Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	acalabrutinib adverse events Bruton tyrosine kinase inhibitor chronic lymphocytic leukemia ibrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1b57d9d157d496799b9fdf515094b55
record_format	dspace
spelling	oai:doaj.org-article:b1b57d9d157d496799b9fdf515094b552021-11-08T07:03:50ZMonitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice2234-943X10.3389/fonc.2021.720704https://doaj.org/article/b1b57d9d157d496799b9fdf515094b552021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.720704/fullhttps://doaj.org/toc/2234-943XBruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL; after ≥1 prior therapy); and by the European Medicines Agency (EMA) for adult patients with relapsed/refractory (R/R) MCL and patients with CLL. Ibrutinib treatment can be limited by adverse events (AEs) including atrial fibrillation, arthralgias, rash, diarrhea, and bleeding events, leading to drug discontinuation in 4%–26% of patients. Acalabrutinib, a second-generation BTK inhibitor, is approved by the FDA to treat adult patients with CLL/SLL or MCL (relapsed after 1 prior therapy); and by the EMA to treat adult patients with CLL or R/R MCL. The most common AE associated with acalabrutinib is headache of limited duration, which occurs in 22%–51% of patients, and is mainly grade 1–2 in severity, with only 1% of patients experiencing grade ≥3 headache. Furthermore, acalabrutinib is associated with a low incidence of atrial fibrillation. Zanubrutinib, a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients with MCL who have received ≥1 prior therapy, and is under investigation for the treatment of patients with CLL. In the phase 3 SEQUOIA trial in patients with CLL, the most common grade ≥3 AEs were neutropenia/neutrophil count decreased and infections. This review provides an overview of BTK inhibitor-related AEs in patients with CLL, and strategies for their management.Susan M. O’BrienJennifer R. BrownJohn C. ByrdRichard R. FurmanPaolo GhiaJeff P. SharmanWilliam G. WierdaFrontiers Media S.A.articleacalabrutinibadverse eventsBruton tyrosine kinase inhibitorchronic lymphocytic leukemiaibrutinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acalabrutinib adverse events Bruton tyrosine kinase inhibitor chronic lymphocytic leukemia ibrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	acalabrutinib adverse events Bruton tyrosine kinase inhibitor chronic lymphocytic leukemia ibrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Susan M. O’Brien Jennifer R. Brown John C. Byrd Richard R. Furman Paolo Ghia Jeff P. Sharman William G. Wierda Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
description	Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL; after ≥1 prior therapy); and by the European Medicines Agency (EMA) for adult patients with relapsed/refractory (R/R) MCL and patients with CLL. Ibrutinib treatment can be limited by adverse events (AEs) including atrial fibrillation, arthralgias, rash, diarrhea, and bleeding events, leading to drug discontinuation in 4%–26% of patients. Acalabrutinib, a second-generation BTK inhibitor, is approved by the FDA to treat adult patients with CLL/SLL or MCL (relapsed after 1 prior therapy); and by the EMA to treat adult patients with CLL or R/R MCL. The most common AE associated with acalabrutinib is headache of limited duration, which occurs in 22%–51% of patients, and is mainly grade 1–2 in severity, with only 1% of patients experiencing grade ≥3 headache. Furthermore, acalabrutinib is associated with a low incidence of atrial fibrillation. Zanubrutinib, a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients with MCL who have received ≥1 prior therapy, and is under investigation for the treatment of patients with CLL. In the phase 3 SEQUOIA trial in patients with CLL, the most common grade ≥3 AEs were neutropenia/neutrophil count decreased and infections. This review provides an overview of BTK inhibitor-related AEs in patients with CLL, and strategies for their management.
format	article
author	Susan M. O’Brien Jennifer R. Brown John C. Byrd Richard R. Furman Paolo Ghia Jeff P. Sharman William G. Wierda
author_facet	Susan M. O’Brien Jennifer R. Brown John C. Byrd Richard R. Furman Paolo Ghia Jeff P. Sharman William G. Wierda
author_sort	Susan M. O’Brien
title	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
title_short	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
title_full	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
title_fullStr	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
title_full_unstemmed	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
title_sort	monitoring and managing btk inhibitor treatment-related adverse events in clinical practice
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
work_keys_str_mv	AT susanmobrien monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice AT jenniferrbrown monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice AT johncbyrd monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice AT richardrfurman monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice AT paologhia monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice AT jeffpsharman monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice AT williamgwierda monitoringandmanagingbtkinhibitortreatmentrelatedadverseeventsinclinicalpractice
_version_	1718442938981154816

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Ejemplares similares